To view journal scope & editors or submit a manuscript, please select a specific journal:
Clinical Lung Cancer Impact Factor
CIG Media Group, LP, has announced the debut ISI Impact Factor of 2.393 for Clinical Lung Cancer. This is the first Impact Factor for a journal that has been dedicated to disseminating cutting-edge data to the practicing clinician by providing physicians and healthcare professionals with the most up-to-date, clinically relevant information available.
“Clinical Lung Cancer provides a one-of-a-kind resource for both lung cancer investigators and a growing cadre of multidisciplinary specialists caring for lung cancer patients world-wide. I am happy that we have been able to take a leadership role within the oncology community as evidenced by the strong initial Impact Factor for the journal,” says Dr. David Gandara, Editor-in-Chief of Clinical Lung Cancer.
Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. The journal publishes a variety of content including comprehensive reviews and original studies. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer, with an emphasis is on recent scientific developments. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
About CIG Media Group, LP
Dallas-based CIG Media Group, LP, is a subsidiary of Medical Media Holdings, LLC. Founded in 1996, CIG Media Group, LP, is the premier publisher of peer-reviewed, tumor-specific medical oncology journals: Clinical Lung Cancer, Clinical Colorectal Cancer, Clinical Breast Cancer, Clinical Lymphoma & Myeloma, and Clinical Ovarian Cancer. All of the company’s established journals are indexed in PubMed. Each year, CIG Media Group, LP, also publishes multiple tumor-specific journal supplements that provide oncology professionals with opportunities to earn American Medical Association–accredited continuing medical education credits. For more information about CIG Media Group, LP, and its clinical oncology journals, please visit www.cigjournals.com.